USA – Moderna sends South Africa variant-specific vaccine for clinical study

Moderna has shipped doses of a variant-specific vaccine candidate against the COVID-19 variant first discovered in South Africa, otherwise known as B.1.351, to the US National Institutes of Health (NIH) for clinical study.

The company also said in a statement that it has completed manufacturing of clinical trial material for the new vaccine candidate, called mRNA-1273.351.

The shipped doses will be used for a Phase I clinical trial, to be led and funded by the NIH’s National Institute of Allergy and Infectious Diseases (NIAID).

To address new and emerging strains of COVID-19, Moderna said in a statement that it is pursuing two strategies against variants…